Presentations & posters
Selection of relevant presentations and posters since 2007
-
2019
- Combination therapy for the treatment of melioidosis
K. B. Barnes, M. I. Richards, C. Bentley, A. Vente and S. V. Harding
-
2018
- Finafloxacin demonstrates utility in treating Burkholderia pseudomallei in vivo
K. B. Barnes, M. I. Richards, A. Vente and S. V. Harding
- Treatment with finafloxacin is effective in a murine model of melioidosis
K. B. Barnes, M. I. Richards, A. Vente and S. V. Harding
-
2017
- The efficacy of finafloxacin against biological threat agents
S. V. Harding, K. B. Barnes, M. I. Richards and A. Vente
- Efficacy of Finafloxacin against Francisella tularensis strain SchuS4
S. V. Harding, K. B. Barnes, K. A. Hamblin, M. I. Richards, A. Vente and H. S. Atkins
-
2016
- Finafloxacin as a novel prophylaxis for Burkholderia pseudomallei infection
S. Harding, K. Barnes, K. Hamblin, M. Richards, A. Vente and H. Atkins
- Exploitation of industrial products for the treatment of BWA's
S. Harding, K. Barnes, K. Hamblin, M. Richards, A. Vente and H. Atkins
-
2015
- Rapid Activity of Finafloxacin in Patients with Urinary Tract Infections and Pyelonephritis Evaluated in Phase 2 Clinical Studies
A. Vente, H. Patel, P. A. Tambyah, D. Fisher, W. Stubbings, M. Lückermann, C. Bentley , H. Labischinski and A. Dalhoff
- Safety and Efficacy of Finafloxacin versus Ciprofloxacin in the Treatment of Hospitalized Patients with complicated Urinary Tract Infections and Pyelonephritis Determined in a Phase 2 Clinical Study
F. Wagenlehner, M. Nowicki, C. Bentley, M. Lückermann, S. Wohlert, C. Fischer, A. Vente and K.G. Naber
- Finafloxacin prophylaxis protects against acute inhalation murine melioidosis
K. Barnes, K. A. Hamblin, H. S. Atkins, A. Vente and S. V. Harding
- Efficacy of Finafloxacin against Francisella tularensis strain SchuS4
S. V. Harding, K. B. Barnes, K. A. Hamblin, A. Vente and H. S. Atkins
-
2014
- Efficacy of the investigational fluoroquinolone Finafloxacin in a murine inhalational model of melioidosis
S. Harding, K. Barnes and A. Vente
- Efficacy of the Investigational Fluoroquinolone Finafloxacin against Resistant Staphylococci as Compared to Ciprofloxacin, Levofloxacin, and Moxifloxacin
I. Morrissey, S. Hawser , A. Vente and A. Dalhoff
- In vitro Evaluation of the Novel Fluoroquinolone Finafloxacin against Yersinia pestis
K. Barnes, A. Vente, M. Richards and S. Harding
-
2013
- Efficacy of the Investigational Fluoroquinolone Finafloxacin in a Murine Inhalational Model of Melioidosis
S. Harding, K. Barnes, A. Simpson and A. Vente
-
2012
- Comparison of Postantibhtiotic Effects of Finafloxacin and other Fluoroquinolones
C. Y. Goh, S. B. Ng, M. Everett and A. Vente
- A Phase I Study to Determine Safety, Tolerability and Pharmacokinetics (PK) of Intravenous Doses of Finafloxacin HCl in Healthy Subjects
M. Lückermann, H. Patel, L. Mooney, S.-E. Wohlert, C. Fischer, C. Bentley and A. Vente
-
2011
- Effects of Varying MIC parameters on the in vitro Activity of Finafloxacin
S. Hawser, M. Hackel, S. Bouchillon and A. Vente
- Comparative Activity of Finafloxacin and Moxifloxacin against Anaerobes
S. Hawser, M. Hackel, S. Bouchillon and A. Vente
- Spectrum of in Vitro Activity of Finafloxacin, a Novel 8-cyano Fluoroquinolone, against 985 Aerobic Gram-Positive and Gram-Negative Bacteria
S. Hawser, M. Hackel, S. Bouchillon and A. Vente
- Investigation of In Vitro Antagonistic and Synergistic Effects of Finafloxacin in Combination with Other Antibiotics
C. Y. Goh, S. B. Ng, M. Everett and A. Vente
-
2010
- Pharmacokinetics / Pharmacodynamics of Finafloxacin in the Murine Thigh Infection Model with S. aureus and E. coli
W. J. Weiss, M. Pulse, P. Renick, J. Simecka, W. Stubbings and H. Labischinski
- Determination of the Effect of Age and Gender on the Pharmacokinetics (PK) and Tolerability of a Single Dose of Finafloxacin HCl (FIN) in Healthy Volunteers
L. Mooney, M. Murphy, M. Kabbaj, A. Vente, H. Labischinski and D. Swearingen
- In vitro Investigation of Finafloxacin Under Conditions Simulating Lower Respiratory Tract Infection
C. Y. Goh, F. Goh and W. Stubbings
- Finafloxacin Exhibits Enhanced Activity Under Acidic And Anaerobic Conditions
C. Y. Goh, H. Labischinski and W. Stubbings
- Antibacterial Activity of Finafloxacin Against Isogenic Pseudomonas aeruginosa (Pa) Isolates Expressing Combinations of Defined Mechanisms of Fluoroquinolone (FQ) Resistance and Propensity to Select for Resistance
F. Goh, A. Schnasse, H. Labischinski, W. Stubbings and P. Heisig
-
2009
- Activity of the Investigational Fluoroquinolone Finafloxacin Against Ciprofloxacin-Sensitive and –Resistant Acinetobacter baumannii
P. G. Higgins, W. Stubbings, H. Wisplinghoff and H. Seifert
- Antibacterial activity of finafloxacin against isogenic Escherichia coli isolates expressing combinations of defined mechanisms of fluoroquinolone resistance
N. Emrich, A. Heisig, W. Stubbings, H. Labischinski and P. Heisig
- Activity of the Investigational Fluoroquinolone Finafloxacin and Seven Other Antimicrobials Agents Against 83 Obligately Anaerobic Bacteria
R. Schaumann, G. H. Genzel, W. Stubbings, C. S. Stingu, H. Labischinski and A. C. Rodloff
-
2008
- New Fluoroquinolone Finafloxacin HCl (FIN): Route of Synthesis, Physicochemical Characteristics and Activity under Neutral and Acid Conditions
S-E. Wohlert, T. Jaetsch, B. Gallenkamp, H. J. Knops, N. Lui, M. Preiss, D. Haebich and H. Labischinski
- Effect of pH on the In Vitro Activity of Finafloxacin against Gram-negative and Gram-positive Bacteria
M. Kresken, B. Körber-Irrgang, H. Labischinski and W. Stubbings
- Antimicrobial Activity of Finafloxacin (FIN) against Helicobacter pylori In Vitro and In Vivo
A. Buissonnière, H-O. Werling, B. Bergey, P. Lehours, W. Stubbings, H. Labischinski and F. Megraud
- Comparison of Methods for Finafloxacin MIC Testing at Acidic and Neutral pH
A. Engelhardt, A. Yusof, P. Ho, C. Johansson and K. Sjöström
- MIC Testing of Helicobacter pylori using Etest® Finafloxacin and the Reference Agar Dilution Method
A. Engelhardt, A. Yusof, P. Ho, C. Johansson and K. Sjöström
- Bactericidal Activity Of Finafloxacin Against Difficult To Kill Growth Forms of Escherichia coli
C. Y. Goh, F. Goh, W. Stubbings, H. P. Kroll and H. Labischinski
- Selection and Characterisation of Finafloxacin, Ciprofloxacin and Levofloxacin Resistant Mutants of Escherichia coli
P. Leow, W. Stubbings and H. Labischinski
- Pharmacokinetics (PK) and In Vivo Efficacy of Oral Finafloxacin (FIN) and Comparators in Rodent Models of Systemic Infection
R. Endermann, C. Ladel, W. Stubbings and H. Labischinski
- In Vivo Efficacy of Finafloxacin in Difficult to Treat Animal Models of Infection
R. Endermann, C. Ladel, W. Stubbings and H. Labischinski
- Comparative Activity Between Finafloxacin (FIN) and Other Fluoroquinolones Against Bacterial and Eukaryotic Type II Topoisomerases
M. T. Muller, W. Stubbings and A. Vente
- In Vitro Toxicological Profiling of Finafloxacin
G. Schmuck, G. Wasinska-Kempka, A. Vente and H. Labischinski
- A Phase I Study to Determine Safety, Tolerability and Pharmacokinetics (PK) of Finafloxacin (FIN) in Healthy Subjects
H. Patel, A. Andresen, H-D. Heilmann, M. Seiberling, L. Lopez, R. Pokorny and H. Labischinski
- Urinary Pharmacokinetics and Bactericidal Activity of Finafloxacin (FIN) (800mg) in Healthy Volunteers Receiving a Single Oral Dose
F. M. E. Wagenlehner, C. Wagenlehner, B. Blenk, H. Blenk, W. Stubbings, H. Patel, S. Schubert, A. Dalhoff and K. G. Naber
-
2007
- Friulimicin B Inhibits Cell Wall Biosynthesis through Complex Formation with Bactoprenol-Phosphate
T. Schneider, K. Gries, I. Wiedemann, S. Pelzer, H. Labischinski and H. G. Sahl
- Distinct Mode of Action of the Lipopeptide Antibiotic Friulimicin B and the Lipodepsipeptide Daptomycin: A Proteomic Study
D. Zuehlke, B. Voigt, M. Hecker, S. Jordan, T. Mascher, S. Pelzer and H. Labischinski
- Comparative In Vitro Activities of the Novel Antibacterial Friulimicin B and Other Antibacterial Agents Against Selected Aerobic Gram-positive Bacteria
M. Kresken, J. Brauers, B. Körber-Irrgang, H. Labischinski and S. Pelzer
- Comparative in vitro Activity of the Novel Lipopeptide Friulimicin B with Daptomycin; the Effect of Inoculum, Pulmonary Surfactant and Calcium
H. Priefert, L. Bylund, S. Pelzer, A. Vente and H. Labischinski
- Activity of Friulimicin B and Five Other Antimicrobial Agents against 179 Gram-Positive Obligatory Anaerobic Bacteria
R. Schaumann, D. Adler, S. Pelzer, H. Labischinski and A. C. Rodloff
- Resistance Studies with Friulimicin B and Daptomycin
W. Stubbings, W. Wu, H. Priefert, S. Pelzer, A. Vente, M. Everett and H. Labischinski
- Activity of Friulimicin B Against Glycopeptide and Daptomycin Non-susceptible S. aureus
P. McGhee, T. Bogdanovich, K. Credito, S. Pelzer, H. Priefert, H. Labischinski and P. C. Appelbaum
- Comparative Analysis of the Bactericidal Activities of Friulimicin B, Daptomycin, Tigecycline, and Vancomycin against Difficult to Treat Isolates of S. aureus and S. pneumoniae
S. Schubert, A. Dalhoff, S. Pelzer and H. Labischinski
- Determination of the Predictive PK/PD Parameter for the Efficacy of Friulimicin B in a Murine Staphylococcal Thigh Muscle Infection
M. Glenschek-Sieberth, S. Pelzer, H. Labischinski, J. Schuhmacher and R. Endermann
- Friulimicin B Shows Good Efficacy in a Staphylococcal Murine Abscess Infection
H. Labischinski, M. Glenschek-Sieberth and R. Endermann
- Friulimicin B, a Cyclic Lipopeptide, Exhibits Potent Efficacy in a Murine Pneumococcal Pneumonia Model
R. Endermann, A. Vente and H. Labischinski
- Finafloxacin HCl - a novel experimental fluoroquinolone with monotherapeutic potential for Helicobacter pylori eradication
A. J. Bishop, H. Labischinski, W. Stubbings and A. D. Buss